Comparison of Insulin Detemir and Insulin Glargine in Type 1 Diabetes

Treatment with twice-daily insulin detemir or once-daily insulin glargine, each in combination with insulin aspart, resulted in similar glycemic control. To compare glycemic control and risk of hypoglycemia of twice-daily insulin detemir with once-daily insulin glargine in subjects with Type 1 diabetes. Methods In this 26-week, multicenter, open-label, parallel-group trial, 320 subjects with Type 1 diabetes received either insulin detemir twice daily or insulin glargine once daily. each in combination with premeal insulin aspart.

The results showed that after 26 weeks, HbA(1c) had decreased from 8.8 to 8.2% in the insulin detemir group and from 8.7 to 8.2% in the insulin glargine group. Home-measured fasting plasma glucose (PG) was lower with insulin glargine than with insulin detemir (7.0 vs. 7.7 mmol/l, P < 0.001). The overall shape of the home-measured nine-point PG profiles was comparable between treatments (P = 0.125). Overall, there was no significant difference in within-subject variation in PG (P = 0.437). Within-subject variation in predinner PG was lower with insulin detemir than with insulin glargine (P < 0.05).

The overall risk of hypoglycemia was similar with no differences in confirmed hypoglycemia. However, the risk of severe and nocturnal hypoglycemia was 72% and 32%, respectively, lower with insulin detemir than with insulin glargine (P < 0.05). Body weight gain was not significantly different comparing insulin detemir and insulin glargine (0.52 kg vs. 0.96 kg, P = 0.193).

From the results it was concluded that,  treatment with twice-daily insulin detemir or once-daily insulin glargine, each in combination with insulin aspart, resulted in similar glycemic control. The overall risk of hypoglycemia was comparable, whereas the risks of both severe and nocturnal hypoglycemia were significantly lower with insulin detemir.

Diabet Med. 2007 Mar 22

Learn about the ONlY Instant Disposable In Office A1c Test:  Studies have shown that by providing the A1c test in the office while the patient is present, can lower A1c by a full point.  Learn about the only 99% accurate disposable A1c test that is CLIA waived and cost less then 10 dollars and reimbursed at least 21 dollars.     https://www.a1ctest.com

================================

Help us keep this newsletter free-update your profile.